433 related articles for article (PubMed ID: 16040401)
1. Peroxisome proliferator-activated receptors and their relevance to dermatology.
Friedmann PS; Cooper HL; Healy E
Acta Derm Venereol; 2005; 85(3):194-202. PubMed ID: 16040401
[TBL] [Abstract][Full Text] [Related]
2. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
[TBL] [Abstract][Full Text] [Related]
3. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
Yumuk VD
Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
[TBL] [Abstract][Full Text] [Related]
4. Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling.
Gardner OS; Dewar BJ; Graves LM
Mol Pharmacol; 2005 Oct; 68(4):933-41. PubMed ID: 16020742
[TBL] [Abstract][Full Text] [Related]
5. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury.
Collino M; Patel NS; Thiemermann C
Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):179-97. PubMed ID: 19124421
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptors and inflammation.
Moraes LA; Piqueras L; Bishop-Bailey D
Pharmacol Ther; 2006 Jun; 110(3):371-85. PubMed ID: 16168490
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
Giaginis C; Tsantili-Kakoulidou A; Theocharis S
Fundam Clin Pharmacol; 2007 Jun; 21(3):231-44. PubMed ID: 17521292
[TBL] [Abstract][Full Text] [Related]
8. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer.
Sertznig P; Seifert M; Tilgen W; Reichrath J
J Cell Physiol; 2007 Jul; 212(1):1-12. PubMed ID: 17443682
[TBL] [Abstract][Full Text] [Related]
9. The human semaphorin 6B gene is down regulated by PPARs.
Collet P; Domenjoud L; Devignes MD; Murad H; Schohn H; Dauça M
Genomics; 2004 Jun; 83(6):1141-50. PubMed ID: 15177567
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
Brown JD; Plutzky J
Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
[TBL] [Abstract][Full Text] [Related]
11. PPAR ligands: are they potential agents for cardiovascular disorders?
Balakumar P; Rose M; Singh M
Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434
[TBL] [Abstract][Full Text] [Related]
12. Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha.
Gani OA; Sylte I
J Mol Graph Model; 2008 Sep; 27(2):217-24. PubMed ID: 18547851
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptors: potential therapeutic targets in lung disease?
Denning GM; Stoll LL
Pediatr Pulmonol; 2006 Jan; 41(1):23-34. PubMed ID: 16267824
[TBL] [Abstract][Full Text] [Related]
14. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
Blaschke F; Takata Y; Caglayan E; Law RE; Hsueh WA
Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592
[TBL] [Abstract][Full Text] [Related]
15. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR).
Peraza MA; Burdick AD; Marin HE; Gonzalez FJ; Peters JM
Toxicol Sci; 2006 Apr; 90(2):269-95. PubMed ID: 16322072
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptors and acute lung injury.
Cuzzocrea S
Curr Opin Pharmacol; 2006 Jun; 6(3):263-70. PubMed ID: 16580256
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases.
Sertznig P; Seifert M; Tilgen W; Reichrath J
Am J Clin Dermatol; 2008; 9(1):15-31. PubMed ID: 18092840
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the 'future' in dermatology therapeutics?
Gupta M; Mahajan VK; Mehta KS; Chauhan PS; Rawat R
Arch Dermatol Res; 2015 Nov; 307(9):767-80. PubMed ID: 25986745
[TBL] [Abstract][Full Text] [Related]
20. Variations in the genes encoding the peroxisome proliferator-activated receptors alpha and gamma in psoriasis.
Mössner R; Kaiser R; Matern P; Krüger U; Westphal GA; Brockmöller J; Ziegler A; Neumann C; König IR; Reich K
Arch Dermatol Res; 2004 Jun; 296(1):1-5. PubMed ID: 15083308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]